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Although multiple members of the phosphatidylinositol-3-kinase pathway (PI3K) are targeted by 
germline or somatic mutations, functional mutations in the three akt isoforms have proven elusive. 
This is somewhat surprising, as AKT represents a key node in the PI3K pathway, exhibiting trans-
forming activity when incorporated into the AKT8 retrovirus. A recent report in Nature identifies a 
transforming E17K PH domain mutation in akt1 in breast (8%), colorectal (6%), and ovarian (2%) 
cancers. E17K-akt1 transforming activity appears due to PtdIns(3,4)P2- and PtdIns(3,4,5)P3-inde-
pendent recruitment of AKT1 to the membrane. This novel observation raises important theoretical 
and clinical questions.Introduction
The PI3K pathway is more frequently 
activated  by  genomic  aberrations 
than  any  other  signaling  pathway 
across many  cancer  lineages  (Table 
1).  Multiple  pathway  components 
are  targeted by  germline  or  somatic 
mutation,  amplification,  rearrange-
ment,  methylation,  overexpression, 
and  aberrant  splicing  (Hennessy  et 
al., 2005; Karni et al., 2007; Kumar and 
Hung,  2005;  Manning  and  Cantley, 
2007). A major challenge in determin-
ing  the  frequency  and  spectrum  of 
mutations  resides  in  the  difficulty  of 
differentiating the core PI3K pathway 
from  the  wider  PI3K  signaling  net-
work  that  includes  interactions  with 
the  p53,  RAS/MAPK,  TGFβ,  NfκB, 
WNT, and other pathways (Hennessy 
et al., 2005; Kumar and Hung, 2005; 
Manning  and  Cantley,  2007).  The 
PI3K  pathway  is  also  activated  by 
many cell surface receptors as well as 
intracellular linkers and signaling mol-
ecules  (Table  1).  Thus, most  human 
cancers exhibit activation of the PI3K 







sclerosis complex integrates informa-104  Cancer Cell 12, August 2007 ©2007tion  from  the  growth  factor-sensing 
arm  of  the  network,  encompassing 
PI3K, PTEN, and AKT, and the energy-
sensing  LKB1/AMPK  arm,  with  the 
latter  being  dominant,  passing  the 
message  to  Rheb,  mTOR,  and  other 
downstream  mediators.  This  rep-
resents  a  simplistic  model,  as  each 
member  of  the pathway has multiple 
additional  inputs  and  outputs  (Hen-
nessy et al., 2005; Kumar and Hung, 
2005;  Manning  and  Cantley,  2007). 
In  Drosophila,  mutations  upstream 
of TSC1/2 alter cell number and size, 
while  those  downstream  of  TSC1/2 
affect only cell size, supporting the con-
cept  that  the pathway bifurcates and 










and  outcomes  or  act  in  concert  to 
stimulate the pathway.




the panoply of known PI3K pathway  Elsevier Inc.aberrations  (Carpten  et  al.,  2007). 
This mutation  results  in  PI3K-inde-
pendent  membrane  recruitment  of 
AKT1,  recapitulating  the  effects  of 




els  than  myristoylated  AKT.  Mem-
brane  targeting  is  critical  to  this 
transforming activity.
Arising Questions
As with  all  major  new  observations, 
this  report  raises  important  ques-
tions  for  the  future.  The mechanism 
by  which  the  E17K  mutation  in  the 
PH  domain  increases  membrane 
association  and  AKT  activation  in 
the  absence  of  PtdIns(3,4)P2  or 
PtdIns(3,4,5)P3 while  still  facilitating 
activation  in  the presence of growth 
factors  requires  further  exploration. 
In addition, the finding that PDK1 and 
PDK2 sites of E17K-AKT1 are phos-
phorylated  raises  the  question  of 
whether  PDK1  and  TORC2  are  con-
stitutively  associated with  the mem-
brane  in  cells  with  mutant  akt1.  Is 
recruitment of the mutant PH domain 
to the membrane due to altered bind-
ing  specificity  for  other  membrane 
phospholipids  (e.g.,  PI4,5P2,  phos-
phatidylcholine,  phosphatidylserine) 
or,  as  PH  domains  can  also  bind 
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akt1 PH domain mutation 8% 17,100 breast
6% 9000 colorectal
2% 400 ovary










lkb1 Peutz Jeghers mutation 30%  52,300 lung





pik3cb amplification 5% 1000 serous epithelial ovarian cancer
5% 13,000 breast cancer





p85 activating mutations rare ovary, bowel, glioma
p70s6k amplification ≤30% 64,000 breast
p70s6k aberrant splicing unknown unknown











egfr mutationc 10% 17,400 lung cancerj
egfr amplification variable breast, lung, bowel, head, and neck
her2 amplification 10%–20% 21,500–43,000 breast cancer
8% 1600 high-grade ovarian cancer
<10% <17,500 lung cancer
her2 mutationd <5% 8700 lung cancer 
bcr/abl translocation >90% >4050 CML
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Previewskit mutation >80% GIST
12% ovarian germ cell tumors
variable sarcomas






pdgfr mutation rare GIST
>80% dermatofibrosarcoma protuberans
met mutation 10% 17,400 lung
amplification 10% 14,900 colorectal
mutation 27% head and neck
flt3 mutation 20%–25% AML
Estrogen receptor expression 60%–70% 128,000–150,000 breast cancer
apik3ca mutations are late events in endometrial, esophagus, and likely breast cancers.












Molecule Alteration Frequency Approximate Cases 
per Year (U.S.)
Tumor Lineageproteins, does  it  interact with a pro-
tein  complex?  AKT1  functions  both 
in  the membrane and nucleus. What 
regulates the dissociation of activated 
E17K-akt1  from  the  membrane  and 
translocation to the nucleus? Alterna-
tively, does E17K-akt1 mediate trans-
formation  as  a  membrane  protein? 
What  is  the  frequency  of  E17K-akt1 
mutations in other tumor lineages and 
tumor  subtypes?  Similarly,  is  E17K-










al.,  2003;  Hutchinson  et  al.,  2004). 
The  mechanisms  underlying  these 
functional  differences  are  as  yet 






may  be  less  aggressive,  resulting 
in  improved  outcomes.  A  network 
approach  wherein  the  combinato-
rial  effects  of  genomic  aberrations 
in the PI3K network including E17K-
akt1  are  considered  systematically 
defining  “pathway  activity”  may 
provide  superior  prognostic  and 
predictive power.
The PI3K pathway regulates multiple 
cellular  outcomes,  including  survival, 
growth,  proliferation,  angiogenesis, Elsevier Inc.migration,  metabolism,  and  glucose 
homeostasis,  and  therefore  must  be 
under tight homeostatic control ensur-
ing  that cellular  inputs are  integrated 
into  appropriate  outcomes.  Indeed, 
potent  feedback  and  feedforward 
pathway  networks  are  of  theoreti-
cal  and  therapeutic  importance.  For 
example,  TORC1  complex  inhibition 
with rapamycin analogs increases AKT 
phosphorylation  and  activity  through 
feedback loops (O’Reilly et al., 2006), 
potentially  explaining  the  disappoint-
ing activity of TORC1 complex inhibi-
tors  in  cancer  patients.  A  systems 
biology  approach  to  development  of 
robust  PI3K  network  computational 
models in normal cells integrating the 
effect of aberrations present in cancer 














way  components  (Hennessy  et  al., 
2005).  Clinical  trials  are  underway 
with  inhibitors  targeting  PI3K,  AKT, 
and the TORC1 complex. PI3K path-
way  aberrations  may  render  tumor 
cells more sensitive to pathway inhi-




of  the  PI3K  pathway  to  normal  cel-
lular function, there may be a thera-
peutic  index  that  allows  implemen-
tation  of  PI3K  pathway-targeted 
therapeutics.
The  specific  mutational  aberra-
tion  in  tumors  may  determine  the 
efficacy  of  drugs  targeting  par-
ticular  PI3K  pathway  components. 
Targeting  an  upstream molecule  in 
the  pathway may  have  limited  effi-
cacy  in  patients  with  downstream 
activating  mutations.  As  full  acti-
vation  of  E17K-AKT1  appears  to 
be  dependent  on  phosphorylation 
by PDK1 and PDK2  (Carpten et al., 
2007),  cells  carrying  this  mutation 
may be  sensitive  to  both  upstream 
and  downstream  pathway  inhibi-
tors. Alternatively, as E17K-AKT1  is 
associated  with  the  membrane  in 
the absence of PI3K activity, tumors 
with  E17K-akt1  mutations  may  be 
insensitive to upstream inhibitors.The  E17K-akt1  mutation  questions 







efficacy  in  individuals  with  pik3ca  or 
pten mutations, while an akt2-selective 
inhibitor  may  be  required  in  patients 
with AKT2 amplification.
Implications for the Cancer 
Genome Atlas Pilot Project
The  Cancer  Genome  Atlas  (TCGA) 
will  perform  high-content  analysis 
of DNA copy number, transcriptional 
profiles  for  mRNA  and  regulatory 






progress  in  improving  patient  out-
come. This analysis of 500 gliomas, 
ovarian  cancers,  and  lung  cancers 
is  designed  to  detect  events  that 
occur  with  at  least  5%  frequency. 
Thus,  mutations  with  similar  fre-
quency  to  E17K-akt1  mutations 
should be detected. However, previ-
ous  large-scale  sequencing  efforts 
assessing  all  three  AKT  isoforms 
in  multiple  cancer  lineages  failed 
to  identify  the  E17K-akt1  mutation 
(Greenman et al., 2007; Sjoblom et 
al., 2006). Other aberrations in AKT 
family  members  were  identified, 
including  germline  single-nucleo-
tide polymorphisms and rare (<1%) 
akt2  and  akt3  somatic  mutations 
of  unknown  significance.  This  sug-Cancer Cell 1gests  that  current  high-throughput 
sequencing  technologies  have  the 
potential to “miss” functionally rele-
vant mutations and identifies a need 
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